Clinical and Experimental Dermatology最新文献

{"title":"Correction to: The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis).","authors":"","doi":"10.1093/ced/llaf175","DOIUrl":"10.1093/ced/llaf175","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1486"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and meta-analysis of treatments and outcomes in primary localized cutaneous amyloidosis.","authors":"Qin-Xiao Wang, Qian Ye, Kai-Yi Zhou, Si-Yu Luo, Sheng Fang","doi":"10.1093/ced/llaf081","DOIUrl":"10.1093/ced/llaf081","url":null,"abstract":"<p><strong>Background: </strong>Primary localized cutaneous amyloidosis (PLCA) is a skin-limited disorder characterized histologically by amyloid deposition in the papillary dermis.</p><p><strong>Objectives: </strong>To review current treatment strategies and provide an updated perspective on the treatment of PLCA.</p><p><strong>Methods: </strong>We searched the PubMed, EMBASE and Cochrane Library databases for eligible studies. Studies were divided into those that described nodular amyloidosis (NA) and those that described non-NA. Cohort studies were meta-analysed using a random effects model to evaluate the outcomes of different treatments, while case reports and case series were evaluated using the Mann-Whitney U-test.</p><p><strong>Results: </strong>Overall, 116 studies involving 534 patients were included. Surgery was the most effective treatment option in patients with NA, with statistically significantly better outcomes compared with other treatments. For the non-NA group, 62 case-level studies (79 patients) and 20 cohort studies (418 patients) were analysed separately. Although there were no statistically significant differences between treatments in the case-level studies, biologic agents and Janus kinase (JAK) inhibitors may be promising treatments for refractory lesions. Among the cohort studies, partial response rates of 100.0%, 100.0%, 97.5%, 96.9% and 94.4% were achieved for transcutaneous electrical nerve stimulation, microneedling, laser therapies, topical therapies and systemic immunosuppressants, respectively; complete response rates of 22.2% and 2.5% were achieved for surgical interventions and laser therapies, respectively.</p><p><strong>Conclusions: </strong>This study suggests that surgery is the most effective treatment option for NA, and laser therapy is recommended for patients with non-NA. Biologic agents and JAK inhibitors may be promising treatment options for lesions that do not respond to conventional therapies.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1343-1354"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study.","authors":"Francesca Barei, Paolo Calzari, Elena Pezzolo, Maddalena Napolitano, Mariateresa Rossi, Mario Bruno Guanti, Francesca Caroppo, Anna Belloni Fortina, Cataldo Patruno, Anna Campanati, Tommaso Bianchelli, Giovanni Marco D'Agostino, Eustachio Nettis, Francesco Pugliese, Vincenzo Picone, Ilaria Trave, Emanuele Cozzani, Luca Stingeni, Katharina Hansel, Matilde Dall'Olio, Benedetta Galli, Rosa Coppola, Vincenzo Panasiti, Martina Maurelli, Giampiero Girolomoni, Michela Ortoncelli, Simone Ribero, Angelo Valerio Marzano, Silvia Mariel Ferrucci","doi":"10.1093/ced/llaf062","DOIUrl":"10.1093/ced/llaf062","url":null,"abstract":"<p><strong>Background: </strong>Tralokinumab has demonstrated efficacy in the treatment of atopic dermatitis (AD) in clinical trials and real-world settings. However, there are limited data regarding the long-term use of tralokinumab in real-world settings. Here, we report the findings of a multicentre Italian study conducted to address this knowledge gap.</p><p><strong>Objectives: </strong>To evaluate the drug survival and efficacy of tralokinumab for up to 18 months in 471 patients with severe AD.</p><p><strong>Methods: </strong>Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale, Sleep Disturbance NRS, Dermatology Life Quality Index and Atopic Dermatitis Control Tool (ADCT) scores were recorded for up to 18 months in patients with AD treated with tralokinumab. Drug survival was analysed using the Kaplan-Meier method.</p><p><strong>Results: </strong>The overall drug survival rate was 81.5% at 12 months. A statistically significantly higher rate of drug survival was found in women (P = 0.006, log-rank = 7.49), in patients with no family history of AD (P = 0.02, log-rank = 5.96) and in patients aged ≥ 60 years (P = 0.02; log-rank = 5.6), when considering drug survival due to inefficacy. We found a significant reduction in the clinical scores evaluated, with patients naïve to biologics or Janus kinase inhibitors (JAKi) showing more rapid improvement. In univariate regression analysis, the following characteristics were associated with an increased likelihood of achieving EASI-75 (≥ 75% improvement in EASI vs. baseline): being a woman [odds ratio (OR) 1.61, 95% confidence interval (CI) 1.03-2.53; P = 0.04], having no atopic comorbidities (OR 1.69, 95% CI 1.03-2.78; P = 0.04), having no family history of AD (OR 1.67, 95% CI 1.05-2.65; P = 0.01) and having received no concomitant systemic treatment in the previous 12 months (OR 22.07, 95% CI 2.80-173.69; P = 0.003). In multivariate analysis, only a lack of concomitant systemic treatment in the previous 12 months remained statistically significant (OR 23.04, 95% CI 2.79-190.05; P = 0.004).</p><p><strong>Conclusions: </strong>Significant improvements in clinical scores were found in patients with AD treated with tralokinumab, with patients naïve to biologics or JAKi experiencing more rapid progress.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1373-1384"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A patient with blistering eruption in skin of colour.","authors":"Omar M E Ali, Ala Haqiqi, Rana Salem, Batoul Nasr, Philip Hampton","doi":"10.1093/ced/llaf039","DOIUrl":"10.1093/ced/llaf039","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1469-1472"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yellow firm papules on bilateral lower extremities: a clinicopathological challenge.","authors":"Neha Arora, Maria Leszczynska, Allie Preston, Betsy Furukawa","doi":"10.1093/ced/llaf072","DOIUrl":"10.1093/ced/llaf072","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1476-1479"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatofibrosarcoma protuberans of the scalp treated with formalin-fixed Mohs surgery: a patient's perspective.","authors":"Andrew Affleck","doi":"10.1093/ced/llaf069","DOIUrl":"10.1093/ced/llaf069","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1460-1461"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the number-needed-to-biopsy ratio for melanoma diagnosis by artificial intelligence as a medical device, teledermatology and face-to-face models of care.","authors":"Radhika Bali, Jenny Ga-Yun Chung, Lucy Thomas, Khawar Hussain, Louise Fearfield","doi":"10.1093/ced/llaf120","DOIUrl":"10.1093/ced/llaf120","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1450-1451"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing guselkumab to target itch in disseminated superficial actinic porokeratosis: insights from RNA sequencing.","authors":"Yi-Han Chang, Yi-Kai Hong, Hui-Ching Cheng, Wan-Rung Chen, John A McGrath, Chao-Chun Yang, Chao-Kai Hsu","doi":"10.1093/ced/llaf106","DOIUrl":"10.1093/ced/llaf106","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1433-1436"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-α inhibitor: a systematic review and meta-analysis': risk of cancer recurrence with biologics in psoriasis.","authors":"Aparna Potluru, Yasmin Nikookam","doi":"10.1093/ced/llaf031","DOIUrl":"10.1093/ced/llaf031","url":null,"abstract":"<p><p>This article reviews the findings of Wu et al. regarding the risk of malignancy in patients with psoriasis who were treated with long-term tumour necrosis factor-α inhibitors. While the study found no significant increase in the risk of most cancers, it highlighted a higher risk of nonmelanoma skin cancers, particularly squamous cell carcinoma, in patients with psoriatic arthritis. The article discusses the clinical implications for patients with psoriasis who have a history of malignancy, advocating for a personalized treatment approach, vigilant monitoring and the need for further research to better understand the relationship between biologic therapy and cancer recurrence.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1426-1427"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common variable immunodeficiency 10 due to a novel variant of NFKB2 and presenting as alopecia universalis and vitiligo.","authors":"Lijuan Wang, Bin Zhang","doi":"10.1093/ced/llaf060","DOIUrl":"10.1093/ced/llaf060","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1429-1431"},"PeriodicalIF":3.7,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}